FDA approves Epocal's new glucose test on the epoc Blood Analysis System

Epocal, Inc., a leading edge provider of point of care technology, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market its new glucose test on the epoc Blood Analysis System. Glucose measurements are used for the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus and idiopathic hypoglycemia, and of pancreatic islet cell tumors. The addition of glucose to the epoc BGEM Test Card, which includes in vitro diagnostic tests for pH, pO2, pCO2, Na, K, iCa and Hct (plus calculated values), further expands the clinical utility of the Company's point of care blood gas and electrolyte platform.

"The FDA clearance of glucose represents one of many milestones to come for Epocal and for healthcare as we continue to expand the test menu of the first wireless and cost effective point of care testing system." said Imants Lauks, Epocal President and Founder. "We are very excited to offer an award winning technology that enables hospitals worldwide to improve the delivery of patient care, reduce their operating expenses and operate more efficiently."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Erratic sleep patterns may increase blood pressure among teens who have more abdominal fat